SHR2554 Combined With Endocrine Therapy in Advanced Breast Cancer

StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Enrollment reduced 50% 60 → 30 participants
See other at-risk trials from Henan Cancer Hospital

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment reduced: 60 → 30 participants Show 7 more changesShow less
    • Recruitment opened
    • Interventions modified
    • Trial arms changed: 2 → 1
    • Start date changed from estimate of Sep 30, 2025 to Oct 14, 2025
    • Eligibility criteria expanded, about 18 words
    • Secondary endpoints: details revised at 1 of 5 entries
    • Site details revised
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study is aimed to evaluate the safety and preliminary of all-oral regimen SHR2554 combined with HRS-8080 in advanced breast cancer.
Trial Details
NCT Number NCT07125950
Lead Sponsor Henan Cancer Hospital
Conditions
(from sponsor)		 Advanced Breast Cancer
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov